Metastasis of renal cell carcinoma to the urethra: a rare scenario (2024)

  • Journal List
  • Int Braz J Urol
  • v.47(3); May-Jun 2021
  • PMC7993951

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice

Metastasis of renal cell carcinoma to the urethra: a rare scenario (1)

INTERNATIONAL BRAZ J UROLJournal InformationEditorial BoardOn line SubmissionContentsVideo Section

Int Braz J Urol. 2021 May-Jun; 47(3): 674–677.

Published online 2020 Dec 20. doi:10.1590/S1677-5538.IBJU.2020.0719

PMCID: PMC7993951

PMID: 33621022

Sofia Frade Santos,1 Pedro Oliveira Santos,1 Delfim Doutel,1 and José Venâncio1

Author information Article notes Copyright and License information PMC Disclaimer

INTRODUCTION

Urethral metastasis from renal cell carcinoma is extremely rare, especially in the absence of other metastatic sites.

We present a case of a urethral solitary lesion corresponding to metastasis of a previously diagnosed clear cell renal cell carcinoma.

CASES PRESENTATION

We report the case of a 67-year-old man with an acute episode of gross hematuria with no reported trauma, fever, dysuria, or flank pain. Six months before admission the patient underwent radical left nephrectomy for clear cell renal cell carcinoma (RCC) (Figure-1A). On histological analysis, the tumor invaded the perinephric fat without signs of vascular invasion nor renal sinus invasion. The surgical margins were free of tumor.

Open in a separate window

Figure 1

(A-C) – MRI (A: coronal T2WI) demonstrates a solid renal lesion (horizontal arrow in A) in the left kidney, which was proved to represent renal cell carcinoma. The lesion has irregular contours and heterogeneous signal intensity in T2WI. Polycystic kidney disease is also evident with multiple bilateral renal cysts. Pathological analysis of an endoscopically resected urethral lesion confirmed metastasis from RCC. The tumor cells are CD10 positive (B: CD10, x400). A CT performed two months after resection (C: sagittal image after intravenous contrast injection, arterial phase) shows early enhancement (vertical arrow in C) Along the penile bulb and proximal body of the penis, raising suspicion for regrowth of the metastatic lesion.

The patient's past medical history was also remarkable for chronic renal failure caused by polycystic kidney disease.

A cystourethroscopy revealed a polypoid lesion in the bulbous urethra, along an approximate length of 3cm. It was resected endoscopically and pathological analysis (Figure-1B) confirmed infiltration by carcinoma morphologically similar to the previously resected renal tumor.

He was readmitted two months after endoscopic resection with recurrent hematuria and, subsequently, an acute urinary retention episode. A urinary catheter was placed after some technical difficulties and a hemorrhage.

A computed tomography (CT) (Figure 1-C) showed early enhancement after contrast injection along the penile bulb and proximal body of the penis.

Magnetic resonance imaging (MRI) demonstrated an area of marked T2 heterogeneity (Figures 2A and ​andB)B) involving the bulb and proximal body of the penis with heterogeneous contrast enhancement after gadolinium injection and restrictive on diffusion-weighted imaging (DWI). There was a loss of the regular anatomic planes between the urethra and the surrounding corpus spongiosum.

Open in a separate window

Figure 2

(A-D) – MRI of the urethral metastasis (T2WI). Axial (A) and sagittal (B) images show an area of marked T2 heterogeneity involving the bulb (white arrow in A) and proximal body of the penis (black arrow in B) with a gross cylindrical shape. This lesion has an estimated total extension of 10 cm. It is presumably centred in the urethra (penile, bulbous and membranous) with loss of the normal anatomic planes between the urethra and the surrounding corpus spongiosum. The described lesion corresponds to an area with heterogeneous contrast enhancement after gadolinium injection and restricted diffusion (not shown). Followup MRI of the pelvis after three therapeutic cycles with sunitinib revealed a reduction of the lesion's extension and less heterogeneity, with a better definition of the anatomical planes (C and D). There was no significant restriction to diffusion on DWI (not shown).

These findings were suspicious for regrowth of the metastatic lesion. There were no other suspected metastases.

The patient was considered not eligible for surgery, therefore therapy with sunitinib was initiated. This treatment was temporarily interrupted due to toxicity manifested as asthenia, thrombocytopenia, and cardiotoxicity.

After three therapeutic cycles, there was no recurrence of haematuria nor the development of significant lower urinary tract symptoms. The follow-up MRI (Figures 2C and ​andD)D) showed a reduction in the lesion's extension. The morphological MRI sequences, namely T2-weighted images (T2WI), also confirmed less heterogeneity with a better definition of the anatomical planes. Unequivocal restricted diffusion was no longer evident.

DISCUSSION

Renal cell carcinoma (RCC) is the most common primary renal malignancy, with clear cell RCC being the most frequent histological subtype (1).

The lung, bone, liver, and adrenal gland are common metastatic sites of RCC (1,2). The urethra is one of the infrequent metastatic sites. To our knowledge, there are only eight cases reported in the literature (310), mostly in male patients. Only some represent solitary metastases. In our case, the first metastatic site was the bulbous urethra.

Urethral metastases from other primary sites are also rare, although they are more common than primary urethral tumors (11). The length of the urethra is much larger in men than in women, and that fact may explain the higher rates of urethral metastases in male patients (10). MRI is considered the imaging modality of choice in the assessment of secondary urethral tumors to depict the location, size, and local extension due to proper soft-tissue resolution (11). Extensive secondary tumoral involvement of the urethra presents as a solid nodular or cylindrical mass with heterogeneous contrast enhancement (11), as in our case.

During follow-up imaging (CT and MRI), the recurrence of the histologically proved metastatic lesion was suspected. Clinical and imaging data showed a favourable response to sunitinib, a tyrosine kinase inhibitor used in the treatment of metastatic RCC (1214).

The lesion reported on MRI (Figure-2A-B) caused the loss of the anatomical planes between the urethra and corpus spongiosum. Probably, it is explained by direct extension of the known urethral metastasis to the surrounding corpus spongiosum. The penis is a rare site of metastases and usually affects the corpora cavernosa, while corpus spongiosum invasion is rare (15,16). Most penile metastatic lesions are associated with disseminated metastatic disease and carry an overall poor prognosis (15,17). Urethral and penile metastases may be explained by hematogenous, instrumental and, retrograde lymphatic spread. Dissemination through the urinary excretory system or even direct extension should also be considered (10,11). Spread of tumor cells through the distal urinary excretory system may be favored by the location of a primary tumor in the kidney (close to the renal collecting system) (10).

Infrequent sites of metastatic disease may delay its detection (1), as illustrated by our case. In patients with a known primary malignancy, a metastatic deposit, although rare, should be considered as a cause for the development of lower urinary tract symptoms.

abbreviations

RCCrenal cell carcinoma;
CTcomputed tomography;
MRImagnetic resonance imaging;
DWIdiffusion-weighted imaging;
T2WIT2-weighted images

REFERENCES

1. 1. Diaz de Leon A, Pirasteh A, Costa DN, Kapur P, Hammers H, Brugarolas J, et at. Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma. Radiographics. 2019; 39:998-1016. [PMC free article] [PubMed] [Google Scholar]

2. 2. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007; 189:360-70. [PubMed] [Google Scholar]

3. 3. Goldberg MG, Plaine L. Solitary metastasis of renal cell carcinoma to urethra. Urology. 1990; 35:351-3. [PubMed] [Google Scholar]

4. 4. f*ckata S, Inoue K, Moriki T, Shuin T. A solitary metastasis of renal cell carcinoma to the urethra. J Urol. 2000; 163:1245-6. [PubMed] [Google Scholar]

5. 5. Senzaki H, Okamura T, Tatsura H, Watase H. Urethral metastasis from renal cell carcinoma. Int J Urol. 2003; 10:661-3. [PubMed] [Google Scholar]

6. 6. Cheng CW, Wong WS, Chan LW, Lai FM. A rare cause of acute urinary retention: urethral metastasis from renal cell carcinoma. Int Urol Nephrol. 2004; 36:145-7. [PubMed] [Google Scholar]

7. 7. Bailie J, Wood E, Connolly D, O’Rourke D. Urethral metastasis from renal cell carcinoma: An unusual cause of visible painless haematuria. J Clin Urol.2012, 6:188-90. [Google Scholar]

8. 8. Kravvas G, Varnavas M, Aldujaily S. A unique presentation of an undiagnosed renal cell carcinoma. Case Rep Urol. 2014;2014:840163840163. [PMC free article] [PubMed] [Google Scholar]

9. 9. Pirola GM, Martorana E, Fidanza FA, Bonetti LR, Puliatti S, Bonora A, et at. Rare metastatic sites of renal cell carcinoma: urethra and spermatic cord. Urologia. 2016; 83:214-7. [PubMed] [Google Scholar]

10. 10. Gawlik-Jakubczak T, Matuszewski M, Biernat W. The Metastasis of Renal Cell Carcinoma to the Urethra and Local Tumor Recurrence. Urol Int. 2020; 104:327-9. [PubMed] [Google Scholar]

11. 11. Karaosmanoglu AD, Onur MR, Karcaaltincaba M, Akata D, Ozmen MN. Secondary Tumors of the Urinary System: An Imaging Conundrum. Korean J Radiol. 2018; 19:742-51. [PMC free article] [PubMed] [Google Scholar]

12. 12. Rizzo M, Porta C. Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. Ther Adv Urol. 2017; 9:195-207. [PMC free article] [PubMed] [Google Scholar]

13. 13. Toussi A, Agarwal D, Leibovich B, Potretzke A. Percutaneous resection of metastatic renal cell carcinoma. Int Braz J Urol. 2019; 45:640640. [PMC free article] [PubMed] [Google Scholar]

14. 14. Wang B, Gu W, Wan F, Shi G, Ye D. Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma. Int Braz J Urol. 2019; 45:89-99. [PMC free article] [PubMed] [Google Scholar]

15. 15. Mearini L, Colella R, Zucchi A, Nunzi E, Porrozzi C, Porena M. A review of penile metastasis. Oncol Rev. 2012; 6:e10. [PMC free article] [PubMed] [Google Scholar]

16. 16. Nezu FM, Dhir R, Logan TF, Lavelle J, Becich MJ, Chancellor MB. Malignant priapism as the initial clinical manifestation of metastatic renal cell carcinoma with invasion of both corpora cavernosum and spongiosum. Int J Impot Res. 1998;10:101101. [PubMed] [Google Scholar]

17. 17. Romero Selas E, Lamas Meilán C, Barbagelata López A, Ponce Díaz-Reixa JL, Fernández Rosado E, Alvarez Castelo L, et al. Metastasis de carcinoma renal en cuerpo cavernoso, a propósito de un caso y revisión de la literatura [Metastasis of a renal cell carcinoma in the corpora cavernosum of the penis. Case report and bibliographic review]. Arch Esp Urol. 2006;59:530-2. Spanish. [PubMed] [Google Scholar]

Articles from International Brazilian Journal of Urology : Official Journal of the Brazilian Society of Urology are provided here courtesy of Brazilian Society of Urology

Metastasis of renal cell carcinoma to the urethra: a rare scenario (2024)

FAQs

How long can you live with metastatic renal cell carcinoma? ›

If kidney cancer has spread to surrounding tissues or organs and/or the regional lymph nodes, the 5-year relative survival rate is 72%. If the cancer has spread to a distant part of the body, the 5-year relative survival rate is 15%. Experts measure relative survival rate statistics for kidney cancer every 5 years.

What is the prognosis for metastatic urethral cancer? ›

Urothelial carcinoma is a chemo-sensitive cancer. The median overall survival (OS) time of metastatic urothelial carcinoma (MUC) patients is 17 months following systemic chemotherapy according to a Japanese study (1).

Which renal cell carcinoma has worst prognosis? ›

Chromophobe renal cell carcinoma: This accounts for around 5% of cases. Of these three types, clear cell carcinoma has the worst prognosis, and chromophobe renal cell carcinoma the best, with only 7% of cases going on to affect more distant parts of the body.

Can kidney cancer spread to urethra? ›

Urethral metastasis from renal cell carcinoma is extremely rare, especially in the absence of other metastatic sites.

What is the life expectancy of someone with renal cell carcinoma? ›

Early detection and better treatments have increased the survival rate. The five-year survival rate for Stage I RCC is 90%. And while the life expectancy for people with Stage IV renal cell carcinoma was once a matter of months, many people are now living for several years.

How fast does renal cell carcinoma metastasis? ›

How quickly can kidney cancer spread? How fast kidney cancer spreads is widely variable. Some studies suggest an average growth rates of 0.3 centimeters (cm) per year, but findings vary widely. The grade of the cancer, the person's age and other factors can play a role .

How fatal is urethral cancer? ›

Prognosis for Urethral Cancer

The 5-year survival rates are > 60% for patients with distal tumors and 10 to 20% for patients with proximal tumors.

How bad is cancer of the urethra? ›

In some instances, urethral cancer can be fatal. It may grow and spread to other areas of your body, which is challenging to treat and more likely to be life-threatening.

How aggressive is urethral cancer? ›

Urethral carcinoma has squamous and urothelial features and is associated with HPV infection. Urethral carcinoma is aggressive with a propensity for lymph node and distant organ metastases.

What is the most aggressive renal cell carcinoma? ›

Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is considered one of the most aggressive forms of kidney cancer. A key characteristic of this cancer is the lack of an enzyme called fumarate hydratase (FH).

What is the life expectancy of someone on Cabometyx? ›

Life expectancy: The study suggests that cabozantinib has an advantage here: In this group, participants had passed away within an average of about 10 months (median value), compared to 8 months in the placebo group.

What is the rare form of renal cell carcinoma? ›

Collecting duct RCC is a rare and aggressive type of RCC, accounting for less than 1 percent of renal cell carcinomas. The cancerous cells form irregular tubes inside the tumor.

What is life expectancy with urethral cancer? ›

Life expectancy

According to a recent review of studies, the 5-year survival rate of urethral cancer is 46%, and the 10-year survival rate is 31%. However, the overall survival rate of urethral cancer varies greatly among studies.

Does urethral cancer spread fast? ›

Urethral cancer can metastasize (spread) quickly to tissues around the urethra and is often found in nearby lymph nodes by the time it is diagnosed.

What type of cancer is in the urethra? ›

Squamous cell carcinoma: The most common type of urethral cancer forms in the cells nearest the urethral opening. Transitional cell carcinoma: This type of urethral cancer forms in the area nearest the bladder in women, and in the part of the urethra that goes through the penis and prostate gland in men.

What happens when renal cell carcinoma spreads? ›

Cancer cells spread into the tissue around the tumor in your kidney. The cancer moves from your kidney into your lymph system, which has vessels throughout the body. Kidney cancer cells enter the bloodstream and move to another organ or location in your body.

How long do people live on Cabometyx? ›

Life expectancy: The study suggests that treatment with cabozantinib can prolong life more than everolimus. Half of the patients who received cabozantinib died after about 21 months. This happened after only about 17 months in the group that had treatment with everolimus.

What is the best treatment for metastatic renal cell carcinoma? ›

Checkpoint inhibitors.

Nivolumab (Opdivo) and pembrolizumab (Keytruda) are two of the more common checkpoint inhibitors that can treat metastatic renal cell cancer. Both of these medicines are given through your vein. It takes about 30 minutes for each dose. Nivolumab is given every 2 to 4 weeks.

Top Articles
Latest Posts
Article information

Author: Edwin Metz

Last Updated:

Views: 6482

Rating: 4.8 / 5 (58 voted)

Reviews: 81% of readers found this page helpful

Author information

Name: Edwin Metz

Birthday: 1997-04-16

Address: 51593 Leanne Light, Kuphalmouth, DE 50012-5183

Phone: +639107620957

Job: Corporate Banking Technician

Hobby: Reading, scrapbook, role-playing games, Fishing, Fishing, Scuba diving, Beekeeping

Introduction: My name is Edwin Metz, I am a fair, energetic, helpful, brave, outstanding, nice, helpful person who loves writing and wants to share my knowledge and understanding with you.